Adding certolizumab pegol to background medication is better than adding a placebo for patients with active nonradiographic axial spondyloarthritis, according to a new study…... [Read More]
Search results for: certolizumab pegol
Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…... [Read More]
FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA
Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…... [Read More]
Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…... [Read More]
Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis
In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…... [Read More]
EU Approves Certolizumab Pegol for Pregnant & Nursing Patients
In the EU, certolizumab pegol has been approved for use in pregnant and nursing women with chronic rheumatic disease…... [Read More]
Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
Certolizumab pegol has proved safe and effective for treating patients with plaque psoriasis in a Phase 3 clinical trial…... [Read More]
Certolizumab Pegol Usage Compatible with Breastfeeding
In a small-scale study, researchers found that no, or minimal amounts of, certolizumab pegol transfers from mothers taking the drug to nursing infants…... [Read More]
Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
A recent study found that certolizumab pegol plus methotrexate is effective in achieving sustained remission and low disease activity in patients with early active RA…... [Read More]
Certolizumab Pegol Effective for Treating Rheumatoid Arthritis
NEW YORK (Reuters Health)—Certolizumab pegol, a humanized anti-TNF antibody fragment conjugated to polyethylene glycol, is effective for treating early rheumatoid arthritis (RA) with poor prognostic factors, according to results from the C-OPERA study. Certolizumab is approved in the U.S. and other countries for treating inflammatory diseases, including RA, but its effectiveness in methotrexate-naïve early RA… [Read More]
- 1
- 2
- 3
- …
- 6
- Next Page »